Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)

Chen P(2019)Current status of familial hypercholesterolemia in China: a need for patient FH registry systems Front Physiol 10 1-11

Chen X(2017)Familial hypercholesterolaemia Nat Rev Dis Primers 3 1-20

Zhang S(2020)Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis Circulation. 141 1742-1759

Defesche JC(2016)Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH registry Circ Cardiovasc Genet 9 240-249

Gidding SS(2021)Heterozygous familial hypercholesterolemia: prevalence and control rates Expert Rev Endocrinol Metab 16 175-179

Harada-Shiba M(2018)Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Atherosclerosis. 277 234-255

Hegele RA(2017)Familial hypercholesterolemia phenotype in chinese patients undergoing coronary angiography Arterioscler Thromb Vasc Biol 37 570-579

Santos RD(2015)ODYSSEY FH i and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia Eur Heart J 36 2996-3003

Wierzbicki AS(2015)PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Lancet. 385 331-340

Hu P(2020)Long-term evolocumab in patients with familial hypercholesterolemia J Am Coll Cardiol 75 565-574

Chen P(2019)Current status of familial hypercholesterolemia in China: a need for patient FH registry systems Front Physiol 10 1-11

Chen X(2017)Familial hypercholesterolaemia Nat Rev Dis Primers 3 1-20

Zhang S(2020)Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis Circulation. 141 1742-1759

Defesche JC(2016)Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH registry Circ Cardiovasc Genet 9 240-249

Gidding SS(2021)Heterozygous familial hypercholesterolemia: prevalence and control rates Expert Rev Endocrinol Metab 16 175-179

Harada-Shiba M(2018)Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Atherosclerosis. 277 234-255

Hegele RA(2017)Familial hypercholesterolemia phenotype in chinese patients undergoing coronary angiography Arterioscler Thromb Vasc Biol 37 570-579

Santos RD(2015)ODYSSEY FH i and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia Eur Heart J 36 2996-3003

Wierzbicki AS(2015)PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Lancet. 385 331-340

Hu P(2020)Long-term evolocumab in patients with familial hypercholesterolemia J Am Coll Cardiol 75 565-574